Parker Institute for Cancer Immunotherapy is recognizing its seventh Early Career Researcher Awards class—eight exceptional graduate and postdoctoral researchers from the PICI Network—a consortium of the world’s leading cancer research institutions, who will share up to $2.9 million total in awards to support their research.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
